VNDA

Vanda Pharmaceuticals Inc

Healthcare, Event Driven/Special Sit


Presented:07/31/2015
Price:$12.24
Cap:$0.51B
Current Price:$4.80
Cap:$0.28B

Presented

Date07/31/2015
Price$12.24
Market Cap$0.51B
Ent Value$0.25B
P/E Ratio14.2x
Book Value$3.65
Div Yield0%
Shares O/S41.74M
Ave Daily Vol872,979
Short Int25.53%

Current

Price$4.80
Market Cap$0.28B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Its product portfolio includes Fanapt and Tasimelteon. The Fanapt product is a compound for the treatment of schizophrenia, the oral formulation of, which is currently being marketed and sold in the U.S. by Novartis. The Tasimelteon product is a compound for the treatment of sleep and mood disorders, including circadian rhythm sleep disorders, which is currently in clinical development. Vanda Pharmaceuticals was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Publicly traded companies mentioned herein: Hikma Pharmaceuticals PLC (HIK LN), Novartis AG (NVS), Vanda Pharmaceuticals Inc (VNDA)

Highlights

The presenter has followed Vanda Pharmaceuticals (VNDA) since its early days as a development stage company, prior to Fanapt’s approval and subsequent licensing to Novartis. He is long the stock at current levels ($11) and sees substantial upside potential for Fanapt and the stock as there are multiple potential triggers/ catalysts on the horizon. He noted that investing in VNDA requires belief in Mihael H. Polymeropoulos, who co-founded Vanda and has served as President, Chief Executive Officer and a Director since May 2003. “He runs the company tightly and is dictatorial, but has had success getting drugs approved”, said the presenter. He summarized his bullish view as follows:

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.